A Prospective Open-Label Study of the Effectiveness of Epoetin Beta for Treating Anemic Patients With Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS)

Next Previous
Trial Profile

A Prospective Open-Label Study of the Effectiveness of Epoetin Beta for Treating Anemic Patients With Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Epoetin beta (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Sponsors Roche

    • Most Recent Events

    • 31 Jan 2017 Protocol amendment as there was a change in the primary end-point and also the trial focus.
    • 06 Dec 2016 Preliminary results (n=27) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 01 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top